BridgeBio Pharma Inc.

54.49-3.63-6.25%Vol 722.59K1Y Perf 92.25%
Apr 9th, 2021 16:00 DELAYED
BID54.49 ASK54.50
Open57.54 Previous Close58.12
Pre-Market- After-Market-
 - -  - -%
Target Price
78.89 
Analyst Rating
Strong Buy 1.11
Potential %
44.78 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     40.96
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap8.12B 
Earnings Rating
Price Range Ratio 52W %
60.61 
Earnings Date
12th May 2021

Today's Price Range

54.0158.08

52W Range

25.2473.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.20%
1 Month
-21.84%
3 Months
-16.82%
6 Months
38.51%
1 Year
92.25%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BBIO54.49-3.6300-6.25
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.86-1.01-17.44
Q03 2020-0.97-0.98-1.03
Q02 2020-0.79-1.03-30.38
Q01 2020-0.69-0.78-13.04
Q04 2019-0.70-0.6211.43
Q03 2019-0.55-0.517.27
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th May 2021
Estimated EPS Next Report-0.88
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume722.59K
Shares Outstanding148.96M
Trades Count9.95K
Dollar Volume130.81M
Avg. Volume1.02M
Avg. Weekly Volume549.31K
Avg. Monthly Volume718.04K
Avg. Quarterly Volume1.04M

BridgeBio Pharma Inc. (NASDAQ: BBIO) stock closed at 54.49 per share at the end of the most recent trading day (a -6.25% change compared to the prior day closing price) with a volume of 1.54M shares and market capitalization of 8.12B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 396 people. BridgeBio Pharma Inc. CEO is Neil Kumar.

The one-year performance of BridgeBio Pharma Inc. stock is 92.25%, while year-to-date (YTD) performance is -23.37%. BBIO stock has a five-year performance of %. Its 52-week range is between 25.24 and 73.5, which gives BBIO stock a 52-week price range ratio of 60.61%

BridgeBio Pharma Inc. currently has a PE ratio of -15.60, a price-to-book (PB) ratio of 158.46, a price-to-sale (PS) ratio of 1 065.21, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -64.50%, a ROC of -63.99% and a ROE of -178.56%. The company’s profit margin is -%, its EBITDA margin is -1 940.60%, and its revenue ttm is $8.25 Million , which makes it $0.06 revenue per share.

Of the last four earnings reports from BridgeBio Pharma Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.88 for the next earnings report. BridgeBio Pharma Inc.’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for BridgeBio Pharma Inc. is Strong Buy (1.11), with a target price of $78.89, which is +44.78% compared to the current price. The earnings rating for BridgeBio Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BridgeBio Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BridgeBio Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.00, ATR14 : 4.76, CCI20 : -76.76, Chaikin Money Flow : -0.08, MACD : -0.48, Money Flow Index : 52.54, ROC : -1.17, RSI : 49.43, STOCH (14,3) : 47.58, STOCH RSI : 0.47, UO : 48.51, Williams %R : -52.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BridgeBio Pharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (88.89 %)
7 (87.50 %)
6 (85.71 %)
Moderate Buy
1 (11.11 %)
1 (12.50 %)
1 (14.29 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.11
Strong Buy
1.13
Strong Buy
1.14

BridgeBio Pharma Inc.

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

CEO: Neil Kumar

Telephone: +1 650 391-9740

Address: 421 Kipling Street, Palo Alto 94301, CA, US

Number of employees: 396

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

50%50%

Bearish Bullish

60%40%

News

Stocktwits